Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is JSP Pharmaceutical Manufacturing (Thailand) PCL Operating Margin %?
JSP Pharmaceutical Manufacturing (Thailand) PCLBKK:JSP 80 Operating Margin % is 5.84% as of Mar. 2026, which is 49% below its 10-year median of 11.36. GuruFocus rates BKK:JSP with a GF Score™ of 80/100 and a GF Value™ of ฿3.16 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,955 Consumer Packaged Goods companies, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks better than 76.21% on this metric.
BKK:JSP'
s Operating Margin % Range Over the Past 10 Years
Min: -0.2 Med: 11.36 Max: 12.74
Current: 11.41
BKK:JSP's Operating Margin % is ranked better than 76.21% of 1955
companies
in the Consumer Packaged Goods industry
Industry Median: 5.3
vs BKK:JSP: 11.41
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
JSP Pharmaceutical Manufacturing (Thailand) PCL Operating Margin % Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:JSP vs KHC, GIS: Operating Margin % Comparison
For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL Operating Margin % vs Consumer Packaged Goods Industry
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a Operating Margin % of 5.84% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. This is 49% below median its historical median of 11.36. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #465 out of 1955 companies in the Consumer Packaged Goods industry, placing it in the top 23.8%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Operating Margin % too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Operating Margin % of 5.84% is 49% below median its 10-year median of 11.36. The Consumer Packaged Goods industry median Operating Margin % is 5.30. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 5.84% is 10.2% above this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #465 out of 1955 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Operating Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #465 out of 1955 companies for Operating Margin %. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the top 24% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 5.30. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 5.84% is 10.2% above this benchmark. While the company's 10-year median is 11.36 vs. the industry median of 5.30, JSP Pharmaceutical Manufacturing (Thailand) PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Consumer Packaged Goods company?
The median Operating Margin % among Consumer Packaged Goods companies is 5.30, based on 1,955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Operating Margin % of 5.84% is 10.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median Operating Margin % is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Operating Margin % is 5.84%, which is 49% below median its own 10-year median of 11.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.16, compared to a current price of ฿1.78 — trading 43.7% below its estimated fair value. The current Operating Margin % is 5.84%, which is 49% below median its 10-year median of 11.36 and 10.2% above the Consumer Packaged Goods industry median of 5.30. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current Operating Margin % is 5.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.78 is trading 43.7% below its estimated GF Value™ of ฿3.16.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.
Key valuation signals for BKK:JSP:
Operating Margin %: 5.84% (49% below median its 10-year median of 11.36)
GF Value™: ฿3.16 vs. price of ฿1.78 (43.7% below fair value)
Industry Position: 10.2% above the Consumer Packaged Goods median (#465 of 1955)
No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
80GF Score
Get the complete analysis for BKK:JSP
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP has been successfully added to your 
